Page 44 - Read Online

Abe et al. Mini-invasive Surg 2023;7:28 https://dx.doi.org/10.20517/2574-1225.2023.15 Page 7 of 14

Table 1. Baseline clinical characteristics between the groups
RAMIE P value
Total MIE All Phase
Variables phase Phase I Phase II III MIE vs. RAMIE
n = 292 n = 208 n = 84 n = 28 n = 14 n = 42 All Phase Phase II &
phase I III
Age, years, median 68 69 67 68.5 67 66 0.379 0.974 0.286
[range] [28-84] [28-83] [42-84] [46-83] [56-77] [42-84]
Gender, n (%) 0.754 0.539 0.461
Male 226 (77%) 162 (78%) 64 (76%) 23 (82%) 10 (71%) 31 (74%)
Female 66 (23%) 46 (22%) 20 (24%) 5 (18%) 4 (29%) 11 (26%)
2
BMI (kg/m ), n (%) 0.551 0.101 0.461
< 18.5 50 (17%) 34 (16%) 16 (19%) 2 (7%) 3 (21%) 11 (26%)
18.5-25 213 (73%) 151 (73%) 62 (74%) 26 10 (71%) 26 (62%)
(93%)
> 25 29 (10%) 23 (11%) 6 (7%) 0 (0%) 1 (7%) 5 (12%)
CCI, n (%) 0.171 0.72 0.038
0 113 (39%) 83 (40%) 30 (36%) 9 (32%) 3 (21%) 18 (43%)
1 69 (24%) 45 (22%) 24 (29%) 8 (29%) 5 (36%) 11 (26%)
2 50 (17%) 32 (15%) 18 (21%) 4 (14%) 5 (36%) 9 (21%)
> 3 60 (21%) 48 (23%) 12 (14%) 7 (25%) 1 (7%) 4 (9%)
ASA-PS, n (%) 0.131 0.639 0.143
1 51 (17%) 31 (15%) 20 (24%) 5 (18%) 3 (21%) 12 (29%)
2 176 (60%) 132(63%) 44 (52%) 15 (54%) 8 (57%) 21 (50%)
3 65 (22%) 45 (22%) 20 (24%) 8 (29%) 3 (21%) 9 (21%)
Main tumor location, n (%) 0.161 0.018 0.448
Cervix 12 (4%) 10 (5%) 2 (2%) 0 (0%) 1 (7%) 1 (3%)
Upper 35 (12%) 25 (12%) 10 (12%) 0 (0%) 2 (14%) 8 (19%)
Middle 135 (46%) 102 (49%) 33 (39%) 10 (36%) 5 (36%) 18 (43%)
Lower 85 (29%) 52 (25%) 33 (39%) 15 (54%) 6 (43%) 12 (29%)
Abdomen 25 (9%) 19 (9%) 6 (7%) 3 (11%) 0 (0%) 3 (7%)
Clinical depth of tumor invasion, n 0.838 0.781 0.705
(%)
cT1 77 (26%) 56 (27%) 21 (25%) 7 (25%) 1 (7%) 13 (31%)
cT2 42 (14%) 30 (14%) 12 (14%) 6 (21%) 1 (7%) 5 (12%)
cT3 158 (54%) 110 (53%) 48 (57%) 14 (50%) 12 22 (52%)
(86%)
cT4 15 (5%) 12 (6%) 3 (4%) 1 (4%) 0 (0%) 2 (5%)
Clinical lymph node metastasis, n 0.856 0.627 0.741
(%)
cN0 76 (26%) 56 (27%) 20 (24%) 9 (32%) 4 (29%) 7 (17%)
cN1 121 (41%) 83 (40%) 38 (45%) 13(46%) 3 (21%) 22 (52%)
cN2 85 (29%) 62 (30%) 23 (27%) 5 (18%) 6 (43%) 12 (29%)
cN3 10 (3%) 7 (3%) 3 (4%) 1 (4%) 1 (7%) 1 (2%)
Neoadjuvant therapy, n (%) 0.722 0.401 0.271
None 71 (24%) 53 (25%) 18 (21%) 5 (18%) 2 (14%) 11 (26%)
NAC 204 140 64 (77%) 23 (82%) 1 29
(70%) (68%) 2(86%) (69%)
CRT 17 (6%) 15 (7%) 2 (2%) 0 (0%) 0 (0%) 2 (5%)
ASA-PS: American Society of Anesthesiologists-physical status; BMI: body mass index; CCI: charlson comorbidity index; CRT:
chemoradiotherapy; NAC: neoadjuvant chemotherapy.